دورية أكاديمية

Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)

التفاصيل البيبلوغرافية
العنوان: Early Results from a Phase-2 Study of Varnimcabtagene Autoleucel (IMN-003A), a First-in-India Industry CD19-Directed CAR-T Cell Therapy with Fractionated Infusions for Patients with Relapsed and/or Refractory B Cell Malignancies (IMAGINE Study)
المؤلفون: Damodar, Sharat, Bhat, Sunil *, Nayak, Akshatha *, Mallya, Pooja *, Ram S, Bharath, Joshi, Ravi *, MB, Deepak *, Chougule, Sudarshan *, Joseph, Anne Roshan *, Jakka, Gopinadh *, Dhar, Sudeshna *, Kumar MG, Arun *, Palanisamy, Murugan *, Elluru, Sri Ramulu *, Akheel, Mohammed Manzoor *, Anand, Arun *, Kamat, Anil
المصدر: In Blood 15 November 2022 140 Supplement 1:10343-10344
قاعدة البيانات: ScienceDirect
الوصف
تدمد:00064971
DOI:10.1182/blood-2022-166297